RxDoctor Payments DataLook up a doctor →

Jay Lafleur, MD

Interventional Pain Medicine · Pearland, TXNPI 1245488824

Payments from drug & device makers

$147,188in general payments, 2019–2025

Across 417 payments — averaging $352.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mesoblast, Inc.$120K
  • Curonix LLC$6K
  • Nalu Medical, Inc.$6K
  • Stimwave Technologies Incorporated$3K
  • Vertiflex, Inc.$2K
  • AbbVie$933
  • plus $9K from 46 others

What the payments were for

  • Consulting fees$10,71343%
  • Travel & lodging$4,25017%
  • Food & beverage$9,73139%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$147,188 in reported general payments places this provider in the 95th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$381,206
Medicare patients
201
Services billed
17,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,043$31,637
UbrelvyUbrogepant16$21,102
Lidocaine129$18,209
MovantikNaloxegol Oxalate30$15,021
OxycontinOxycodone Hcl18$14,780
Buprenorphine49$13,984
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen425$12,745
Xtampza ErOxycodone Myristate37$10,776
Morphine Sulfate ErMorphine Sulfate358$8,955
Fentanyl55$6,072
Gabapentin444$5,952
Tizanidine Hcl492$4,288
Oxycodone Hcl195$3,710
Lubiprostone48$3,702
Pregabalin290$3,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$933$21,10216 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl$24$17,179150 claims
Redhill Biopharma Inc.Movantik$142$15,02130 claims
Collegium Pharmaceutical, Inc.Xtampza Er$719$10,77637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →